
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd has demonstrated significant advancement in its diagnostic capabilities, highlighted by the successful launch of its CE-Marked Nu.Q NETs automated assay and its strategic expansion across a multitude of international hospitals, indicating a broadening commercial presence. The company is strategically enhancing its human diagnostics licensing by partnering with industry leaders such as Werfen and Hologic, which is expected to bolster its market penetration and drive future revenue growth. Furthermore, the potential rollout of the Nu.Q Vet Feline Test stands to double the addressable market in companion animal diagnostics, complementing the established success of the Nu.Q Vet Cancer Test, thereby positioning VolitionRX for sustained financial momentum.
Bears say
VolitionRX Ltd faces increased dilution risk, which has prompted a reduction in its price target from $5.00 to $3.00, reflecting concerns over the company’s financial stability and potential shareholder value erosion. This dilution risk may stem from the need for additional capital to support its ongoing research and development efforts in the competitive field of epigenetics and diagnostics. Consequently, these financial challenges contribute to a fundamentally negative outlook on the company’s stock performance.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares